SCHEMBL712707

SCHEMBL712707

Cn1ccnc1COc1ccc(OCc2ccccc2)cc1-c1nc2cc(-c3cccnc3)cnc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 3/20 0.40
CYP11B1 P15538 5/20 0.39
CYP11B2 P19099 5/20 0.39
CYP19A1 P11511 4/20 0.38
MAPT P10636 1/20 0.38
IKBKB O14920 2/20 0.38
PDPK1 O15530 1/20 0.36
LRRK2 Q5S007 1/20 0.35
NTRK1 P04629 1/20 0.35
CSF1R P07333 1/20 0.35
NTRK2 Q16620 1/20 0.35
MAPK1 P28482 1/20 0.35
ALK Q9UM73 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
PDE5A O76074 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712703 0.90 PRMT5 (0.46) PRMT5CYP11B1CYP11B2CYP19A1MAPT
SCHEMBL711188 0.88 CYP3A4 (0.41) PRMT5MAPTALKPDE5APDE4A
SCHEMBL712174 0.87 MAPT (0.36) MAPTALKPDGFRBPDGFRAPDE5A
SCHEMBL2668258 0.85 PDGFRB (0.31) PRMT5CYP11B1CYP11B2CYP19A1PDGFRB
SCHEMBL711177 0.83 PRMT5 (0.42) PRMT5CYP11B1CYP11B2CYP19A1MAPT
SCHEMBL10206538 0.83 MAPT (0.42) PRMT5MAPTIKBKBPDPK1MAPK1
SCHEMBL10206615 0.78 IKBKB (0.47) PRMT5CYP11B1CYP11B2CYP19A1MAPT
SCHEMBL10206607 0.77 CYP3A4 (0.51) PRMT5MAPK1PDGFRBPDGFRAPDE5A
SCHEMBL711039 0.76 PRMT5 (0.41) PRMT5MAPTALK
SCHEMBL10206516 0.76 MCL1 (0.41) MAPTMAPK1PDGFRBPDGFRAPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK PRMT5 2373/4885CYP11B1 1421/4885CYP11B2 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.